nach oben

Indian Journal of Surgery

Erschienen in:

01.02.2012 | Review Article

Liver Transplantation for HCC: A Review

verfasst von: Rahul Kakodkar, A. S. Soin

Erschienen in: Indian Journal of Surgery | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Hepatocellular carcinoma (HCC) often occurs in patients with chronic liver disease or cirrhosis. Liver transplantation for hepatocellular carcinoma has the potential to eliminate both the tumor as well as the underlying cirrhosis and is the ideal treatment for HCC in cirrhotic liver as well as massive HCC in noncirrhotic liver. Limitations in organ availability, necessitate stringent selection of patients who would likely to derive most benefit. Selection criteria have considered tumor size, number, volume as well as biological features. The Milan criteria set the benchmark for tumors that would benefit from liver transplantation but were found to be excessively restrictive. Modest expansion in criteria has also been shown to be associated with equivalent survival. Microvascular invasion is the single most important adverse prognostic factor for survival. Living donor liver transplantation has expanded donor options and has the advantage of lower waiting period and not impacting the non-HCC waiting list. Acceptable outcomes have been obtained with living donor liver transplantation for larger and more numerous tumors in the absence of microvascular invasion. Downstaging of tumors to prevent progression while waiting for an organ or for reduction in size to allow enrolment for transplantation has met with variable success.

Bosch FX, Ribes J, Díaz M, Cléries R (2004) Primary liver cancer: worldwide incidence and trends. Gastroenterology 127(Suppl 1):S5–S16PubMed

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMed

Jemal A et al (2010) Global patterns of cancer incidence and mortality rates and trends. Canc Epidemiol Biomarkers Prev 19:1893–1907

Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R (2000) Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol 95(4):1036–1040PubMed

Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236PubMed

Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434–1440PubMed

Okada S, Shimada K, Yamamoto J, Takayama T, KosugeT YS et al (1994) Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 106:1618–1624PubMed

Minagawa M, Makuuchi M, Takayama T, Kokudo N (2003) Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238:703–710PubMed

Poon RT, Fan ST, Lo CM, Liu CL, Wong J (1999) Intrahepaticrecurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229:216–222PubMed

10.

Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, Tsuneyoshi M (1995) Risk factors for intrahepaticrecurrence in human small hepatocellular carcinoma. Gastroenterology 108:768–775PubMed

11.

Wong R, Frenette C, Gish R (2011) Hepatocellular carcinoma: locoregional and targeted therapies. Gastroenterol Clin North Am 40(3):599–610PubMed

12.

Starzl TE, Porter KA, Brettschneider L, Penn I, Bell P, Putnam CW, McGuire RL (1969) Clinical and pathologic observations after orthotopic transplantation of the human liver. Surg Gynecol Obstet 128(2):327–339PubMed

13.

Penn I (1991) Hepatic transplantation for primary and metastasis cancer of the liver. Surgery 110:726–735PubMed

14.

Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A (1993) Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218(2):145–151PubMed

15.

Mazzaferro V, Regalia E, Doci R, Andreola S, PulvirentiA BF et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693–699PubMed

16.

Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP (2001) Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6):1394–1403PubMed

17.

Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi GL, Adam R, Neuhaus P, Salizzoni M, Bruix J, Forner A, De Carlis L, Cillo U, Burroughs AK, Troisi R, Rossi M, Gerunda GE, Lerut J, Belghiti J, Boin I, Gugenheim J, Rochling F, Van Hoek B, Majno P, Metroticket Investigator Study Group (2009) Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective exploratory analysis. Lancet Oncol 10(1):35–43PubMed

18.

Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R (2004) Results of the first year of the new liver allocation plan. Liver Transpl 10:7–15PubMed

19.

Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T et al (2004) Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 10:36–41PubMed

20.

Miller CM (2008) Ethical dimensions of living donation: experience with living liver donation. Transplant Rev (Orlando) 22:206–209

21.

Singer PA, Lantos JD, Whitington PF, Broelsch CE, Siegler M (1988) Equipoise and the ethics of segmental liver transplantation. Clin Res 36(6):539–545PubMed

22.

Todo S, Furukawa H, Japanese Study Group on Organ Transplantation (2004) Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240(3):451–459, discussion 459–461PubMed

23.

Hwang S, Lee SG, Joh JW, Suh KS, Kim DG (2005) Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 11(10):1265–1272PubMed

24.

Pomfret EA, Lodge JP, Villamil FG, Siegler ML (2011) Should we use living donor grafts for patients with hepatocellular carcinoma? ethical considerations. Liver Transpl 17(Suppl 2):S128–S132PubMed

25.

Dvorchik I, Schwartz M, Fiel MI, Finkelstein SD, Marsh JW (2008) Fractional allelic imbalance could allow for the development of an equitable transplant selection policy for patients with hepatocellular carcinoma. Liver Transpl 14(4):443–450PubMed

26.

Tamura S, Kato T, Berho M, Misiakos EP, O'Brien C, Reddy KR, Nery JR, Burke GW, Schiff ER, Miller J, Tzakis AG (2001) Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 136(1):25–30, discussion 31PubMed

27.

Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P (2001) Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 33(5):1080–1086PubMed

28.

Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M et al (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235:533–539PubMed

29.

Marsh JW, Dvorchik I (2003) Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl 9:693–696PubMed

30.

Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, Mariani L (2011) Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 17(Suppl 2):S44–S57PubMed

31.

Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP (2007) Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7(11):2587–2596PubMed

32.

Decaens T, Roudot-Thoraval F, Hadni-Bresson S, MeyerC GJ, Durand F et al (2006) Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl 12:1761–1769PubMed

33.

D'Amico F, Schwartz M, Vitale A, Tabrizian P, Roayaie S, Thung S, Guido M, del Rio MJ, Schiano T, Cillo U (2009) Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl 15(10):1278–1287PubMed

34.

Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, Sung KB, Ko GY, Park KM, Ha TY, Song GW (2008) Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 14(7):935–945PubMed

35.

Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, Liang TB, Wu LM (2008) Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 85(12):1726–1732PubMed

36.

Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Bog Moon D, Freeman RB (2011) Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 17(Supp l 2):S81–S89PubMed

37.

Volk ML, Vijan S, Marrero JA (2008) A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteria. Am J Transplant 8:839–846PubMed

38.

Vitale A, Volk ML, Gambato M, Zanus G, D’Amico F, Carraro A et al (2010) Estimation of the harm to the waiting list as a crucial factor in the selection of patients with hepatocellular carcinoma for liver transplantation. Transplant Proc 42:1194–1196PubMed

39.

Broelsch CE, Frilling A, Malago M (2005) Should we expand the criteria for liver transplantation for hepatocellular carcinoma—yes, of course? J Hepatol 43:569–573PubMed

40.

Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore A, Harper A, Edwards E (2006) Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 12:1504–1511PubMed

41.

Luca A, Caruso S, Milazzo M, Mamone G, Marrone G, Miraglia R et al (2010) Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol 20:898–907PubMed

42.

Sangiovanni A, Manini MA, Iavarone M, Romeo R, Forzenigo LV, Fraquelli M et al (2010) The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59:638–644PubMed

43.

Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P (2006) Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101:513–523PubMed

44.

Lee JW, Paeng JC, Kang KW, Kwon HW, Suh KS, Chung JK et al (2009) Prediction of tumor recurrence by ¹⁸F-FDGPET in liver transplantation for hepatocellular carcinoma. J Nucl Med 50:682–687PubMed

45.

Kornberg A, Freesmeyer M, Bärthel E, Jandt K, KatenkampK SJ et al (2009) ¹⁸F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 9:592–600PubMed

46.

Ho CL, Yu SC, Yeung DW (2003) ¹¹C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44:213–221PubMed

47.

Ho CL, Chen S, Yeung DW, Cheng TK (2007) Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48:902–909PubMed

48.

Wiesner RH, Freeman RB, Mulligan DC (2004) Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 127(suppl 1):S261–S267PubMed

49.

Compagnon P, Grandadam S, Lorho R, Turlin B, Camus C, Jianrong Y et al (2008) Liver transplantation for hepatocellularcarcinoma without preoperative tumor biopsy. Transplantation 86:1068–1076PubMed

50.

Caturelli E, Bisceglia M, Fusilli S, Squillante MM, Castelvetere M, Siena DA (1996) Cytological vs. microhistological diagnosis of hepatocellular carcinoma: comparative accuracies in the same fine-needle biopsy specimen. Dig Dis Sci 41:2326–2331PubMed

51.

Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, Andriulli A et al (2004) Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 53:1356–1362PubMed

52.

Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B et al (2001) Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 35:254–258PubMed

53.

Müllhaupt B, Durand F, Roskams T, Dutkowski P, Heim M (2011) Is tumor biopsy necessary? Liver Transpl 17(Suppl 2):S14–S25PubMed

54.

Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF (2008) Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 57:1592–1596PubMed

55.

Maturen KE, Nghiem HV, Marrero JA, Hussain HK, Higgins EG, Fox GA, Francis IR (2006) Lack of tumor seeding of hepatocellular carcinoma after percutaneous needle biopsy using coaxial cutting needle technique. AJR Am J Roentgenol 187:1184–1187PubMed

56.

Germani G, Pleguezuelo M, Stigliano R, Burroughs AK (2009) Risk of seeding is reduced by associating diagnostic biopsy with percutaneous ablation for hepatocellular carcinoma. Gut 58:734–735PubMed

57.

Germani G, Gurusamy K, Garcovich M, Toso C, Fede G, Hemming A, Suh KS, Weber A, Kenneth Burroughs A (2011) Which matters most: number of tumors, size of the largest tumor, or total tumor volume? Liver Transpl 17(Suppl 2):S58–S66PubMed

58.

Gouw AS, Balabaud C, Kusano H, Todo S, Ichida T, Kojiro M (2011) Markers for microvascular invasion in hepatocellular carcinoma: where do we stand? Liver Transpl 17(Suppl 2):S72–S80PubMed

59.

Lee HH, Joh JW, Park JH, Lee KW, Heo JS, Choi SH, Kim SJ, Lee SK (2005) Microvascular tumor embolism: independent prognostic factor after liver transplantation in hepatocellular carcinoma. Transplant Proc 37(2):1251–1253PubMed

60.

Esnaola NF, Lauwers GY, Mirza NQ, Nagorney DM, Doherty D, Ikai I, Yamaoka Y, Regimbeau JM, Belghiti J, Curley SA, Ellis LM, Vauthey JN (2002) Predictors of microvascular invasion in patients with hepatocellular carcinoma who are candidates for orthotopic liver transplantation. J Gastrointest Surg 6(2):224–232, discussion 232PubMed

61.

Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A et al (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995–2004PubMed

62.

Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H et al (2008) EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 68:1451–1461PubMed

63.

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY et al (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136:1012–1024PubMed

64.

Boyault S, Rickman DS, de Reyniés A, Balabaud C, Rebouissou S, Jeannot E et al (2007) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42–52PubMed

65.

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S et al (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 361:1437–1447PubMed

66.

Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA et al (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on aunique immune response signature of the liver microenvironment. Canc Cell 10:99–111

67.

Llovet JM, Peña C, Shan M, Lathia C, Bruix J (2008) Biomarkers predicting outcome of patients with advanced hepatocellular carcinoma (HCC) randomized in the phase III SHARP trial. Paper presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases; October 31–November 4, 2008; San Francisco, CA

68.

Parfitt JR, Marotta P, Alghamdi M, Wall W, Khakhar A, Suskin NG et al (2007) Recurrent hepatocellular carcinoma after transplantation: use of a pathological score on explanted livers to predict recurrence. Liver Transpl 13:543–551PubMed

69.

Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I et al (2005) Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11:1086–1092PubMed

70.

Sumie S, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N et al (2008) Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 15:1375–1382PubMed

71.

Shirabe K, Aishima S, Taketomi A, Soejima Y, Uchiyama H, Kayashima H et al (2011) Prognostic importance of the gross classification of hepatocellular carcinoma in living donor-related liver transplantation. Br J Surg 98:261–267PubMed

72.

Fujiki M, Takada Y, Ogura Y, Oike F, Kaido T, Teramukai S, Uemoto S (2009) Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation or hepatocellular carcinoma. Am J Transplant 9:2362–2371PubMed

73.

Cherqui D, Boudjema K, Celebic A, Laurent A, Roudot-Thoraval F (2006) Résection hépatique pour carcinome hépatocellulaire sur foie sain et pathologique en France. Résultats de l’enqueˆte AFC sur la période 1990–2005. In: Boudjema K, Cherqui D (eds) Cancer Hépatocellulaire. Wolters Kluwer, Rueil-Malmaison, pp 183–218

74.

Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, KochM BMW, Weitz J (2011) Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 253:453–469PubMed

75.

Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M (2010) Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 42:341–347PubMed

76.

Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunvén P et al (1990) Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107:521–527PubMed

77.

Torzilli G, Montorsi M, Del Fabbro D, Palmisano A, Donadon M, Makuuchi M (2006) Ultrasonographically guided surgical approach to liver tumours involving the hepatic veins close to the caval confluence. Br J Surg 93:1238–1246PubMed

78.

Kokudo N, Makuuchi M (2004) Current role of portal vein embolization/hepatic artery chemoembolization. Surg Clin North Am 84:643–657PubMed

79.

Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ et al (2009) Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg 250:540–548PubMed

80.

Mergental H, Porte RJ (2010) Liver transplantation for unresectable hepatocellular carcinoma in patients without liver cirrhosis. Transpl Int 23:662–667PubMed

81.

Mergental H, Adam R, Kalicinski P, Ericzon BG, Friman S, Köningsrainer A et al (2007) Liver transplantation for hepatocellular carcinoma in non-cirrhotic livers [abstract]. Liver Transpl 13(suppl 1):S119

82.

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y et al (2005) Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 100:1764–1771PubMed

83.

The Cancer of the Liver Italian Program(CLIP) investigators (2000) Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology 31:840–845

84.

Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338PubMed

85.

Shiina S, Teratani T, Obi S et al (2005) A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129:122–130PubMed

86.

Lin SM, Lin CJ, Lin CC et al (2004) Radiofrequency ablation improves prognosis compared to ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology 127:1714–1723PubMed

87.

Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMed

88.

Llovet JM, Real MI, Montana X et al (2002) Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739PubMed

89.

Majno PE, Adam R, Bismuth H et al (2004) Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 239:150–159

90.

Roayaie S, Frischer JS, Emre SH et al (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 235:533–539PubMed

91.

Yao FY, Hirose R, Laberge J et al (2005) A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11:1505–1514PubMed

92.

Yao FY, Kerlan R, Davern TJ et al (2007) Excellent long-term outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis [abstract]. Hepatology 46(Suppl):309A

93.

De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, Cooper A, Esquivel C, Nguyen MH (2009) Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 9(5):1158–1168PubMed

94.

Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, Samuel D, Bismuth H (2003) Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 238(4):508–518, discussion 518–519PubMed

95.

Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235(3):373–382PubMed

96.

Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C (2009) Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg 250(5):738–746PubMed

97.

Panaro F, Piardi T, Cag M, Cinqualbre J, Wolf P, Audet M (2011) Robotic liver resection as a bridge to liver transplantation. JSLS 15(1):86–89PubMed

98.

Landman MP, Feurer ID, Pinson CW, Moore DE (2011) Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria? HPB (Oxford) 13(11):783–791

99.

Huo TI, Huang YH, Su CW, Lin HC, Chiang JH, Chiou YY et al (2008) Validation of the HCC-MELD for dropout probability in patients with small hepatocellular carcinoma undergoing locoregional therapy. Clin Transplant 22:469–475PubMed

100.

Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R et al (2003) A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 9:684–692PubMed

101.

Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E et al (2002) Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 50:123–128PubMed

102.

Aloia TA, Adam R, Samuel D, Azoulay D, Castaing D (2007) A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg 11:1328–1332PubMed

103.

Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK et al (2011) Radioembolization results in longer time-to progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 140:497–507PubMed

104.

Majno P, Lencioni R, Mornex F, Girard N, Poon RT, Cherqui D (2011) Is the treatment of hepatocellular carcinoma on the waiting list necessary? Liver Transpl 17(Suppl 2):S98–S108PubMed

105.

Pruett TL, Tibell A, Alabdulkareem A, Bhandari M, Cronin DC, Dew MA, Dib-Kuri A, Gutmann T, Matas A, McMurdo L, Rahmel A, Rizvi SA, Wright L, Delmonico FL (2006) The ethics statement of the Vancouver Forum on the live lung, liver, pancreas, and intestine donor. Transplantation 81(10):1386–1387PubMed

106.

Grant D, Fisher RA, Abecassis M, McCaughan G, Wright L, Fan ST (2011) Should the liver transplant criteria for hepatocellular carcinoma be different for deceased donation and living donation? Liver Transpl 17(Suppl 2):S133–S138PubMed

107.

Chan SC, Fan ST, Lo CM, Liu CL, Wei WI, Chik BH, Wong J (2008) A decade of right liver adult-to-adult living donor liver transplantation: the recipient mid-term outcomes. Ann Surg 248(3):411–419PubMed

108.

Efimova EA, Glanemann M, Liu L et al (2004) Effects of human hepatocyte growth factor on the proliferation of human hepatocytes and hepatocellular carcinoma cell lines. Eur Surg Res 36:300PubMed

109.

von Schweinitz D, Faundez A, Teichmann B et al (2000) Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer 85:151

110.

Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J (2007) Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 94(1):78–86PubMed

111.

Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown RS Jr, Ghobrial RM, Fair JH, Olthoff KM, Kam I, Berg CL, A2ALL Study Group (2007) Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7(6):1601–1608PubMed

112.

Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, Zocrato J, Ichai P, Saliba F, Adam R, Castaing D, Azoulay D (2011) Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation. Hepatology 53(5):1570–1579PubMed

113.

Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY, Park KM, Song GW, Jung DH, Kim BS, Moon KM (2007) Small-sized liver graft does not increase the risk of hepatocellular carcinoma recurrence after living donor liver transplantation. Transplant Proc 39(5):1526–1529PubMed

114.

Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M et al (1999) Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397:530–534PubMed

115.

Herman M, Weinstein T, Korzets A, Chagnac A, Ori Y, Zevin D et al (2001) Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 137:14–20PubMed

116.

Schumacher G, Oidtmann M, Rosewicz S, Langrehr J, Jonas S, Mueller AR et al (2002) Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 34:1392–1393PubMed

117.

Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE (1991) Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 68:2095–2100PubMed

118.

Hui IC, Tung EK, Sze KM, Ching YP, Ng IO (2010) Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int 30:65–75PubMed

119.

Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M (2004) mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 10:8421–8425PubMed

120.

Shirouzu Y, Ryschich E, Salnikova O, Kerkadze V, Schmidt J, Engelmann G (2010) Rapamycin inhibits proliferation and migration of hepatoma cells in vitro. J Surg Res 159:705–713PubMed

121.

Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM et al (2005) Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 11:1420–1425PubMed

122.

Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V et al (2007) Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 46:840–848PubMed

123.

Stippel DL, Kasper HU, Schleimer K, Töx U, Bangard C, Hölscher AH, Beckurts KT (2005) Successful use of sirolimusin a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 37:2185–2187PubMed

124.

Elsharkawi M, Staib L, Henne-Bruns D, Mayer J (2005) Completeremission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 79:855–857PubMed

125.

Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E et al (2009) Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 15:1834–1842PubMed

126.

Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I (2008) Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 14:633–638PubMed

127.

Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K et al (2007) De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 83:1162–1168PubMed

128.

Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM (2010) Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 51:1237–1243PubMed

129.

Liang W, Wang D, Ling X, Cao AA, Kong Y, Shang Y, Guo Z, He X (2011) Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis. Liver Transpl; doi:10.1002/lt.22441 [Epub ahead of print]

130.

Schnitzbauer AA, Zuelke C, Graeb C, Rochon J, Bilbao I, Burra P, de Jong KP, Duvoux C, Kneteman NM, Adam R, Bechstein WO, Becker T, Beckebaum S, Chazouillères O, Cillo U, Colledan M, Fändrich F, Gugenheim J, Hauss JP, Heise M, Hidalgo E, Jamieson N, Königsrainer A, Lamby PE, Lerut JP, Mäkisalo H, Margreiter R, Mazzaferro V, Mutzbauer I, Otto G, Pageaux GP, Pinna AD, Pirenne J, Rizell M, Rossi G, Rostaing L, Roy A, Turrion VS, Schmidt J, Troisi RI, van Hoek B, Valente U, Wolf P, Wolters H, Mirza DF, Scholz T, Steininger R, Soderdahl G, Strasser SI, Jauch KW, Neuhaus P, Schlitt HJ, Geissler EK (2010) A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Canc 10:190

131.

Regalia E, Fassati LR, Valente U et al (1998) Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat 5:29–34

132.

Roayaie S, Schwartz JD, Sung MW et al (2004) Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 10:534–540PubMed

133.

Sandroussi C, Guba M, Sandhu L, Dubay D, Ghanekar E, Selzner M et al (2010) Liver transplantation for HCC: characterization of recurrence and outcomes with aggressive multimodal treatment [abstract]. Am J Transplant 10(suppl 4):452

134.

Taketomi A, Fukuhara T, Morita K, Kayashima H, Ninomiya M, Yamashita Y et al (2010) Improved results of a surgical resection for the recurrence of hepatocellular carcinoma after living donor liver transplantation. Ann Surg Oncol 17:2283–2289PubMed

135.

Marangoni G, Faraj W, Sethi H, Rela M, Muiesan P, Heaton N (2008) Liver resection in liver transplant recipients. Hepatobiliary Pancreat Dis Int 7:590–594PubMed

136.

Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J (2010) Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables. Eur J Surg Oncol 36:275–280PubMed

137.

Chen GH, Fu BS, Yang Y, Cai CJ, Lu MQ, Li H et al (2008) Early liver retransplantation versus late liver retransplantation: analysis of a single-center experience. Chin Med J (Engl) 121:1992–1996

138.

Yamashiki N, Sugawara Y, Tamura S, Tateishi R, Yoshida H, Kaneko J et al (2010) Postoperative surveillance with monthly serum tumor markers after living-donor liver transplantation for hepatocellular carcinoma. Hepatol Res 40:278–286PubMed

139.

Toso C, Mentha G, Majno P (2011) Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence. Am J Transplant 11(10):2031–2035PubMed

140.

Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390PubMed

141.

Ohira M, Ohdan H, Mitsuta H et al (2006) Adoptive transfer of TRAIL expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 82:1712–1719PubMed

Titel: Liver Transplantation for HCC: A Review
verfasst von: Rahul Kakodkar
A. S. Soin
Publikationsdatum: 01.02.2012
Verlag: Springer-Verlag
Erschienen in: Indian Journal of Surgery / Ausgabe 1/2012
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI: https://doi.org/10.1007/s12262-011-0387-2

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare

CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare

CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske

Dr. med. Benjamin Meyknecht

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare

CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Liver Transplantation for HCC: A Review

Abstract

Neu im Fachgebiet Chirurgie

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

Fehlerkultur in der Medizin – Offenheit zählt!

Mehr Frauen im OP – weniger postoperative Komplikationen

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

Update Chirurgie

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

S2e-Leitlinie „Distale Radiusfraktur“

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

Current Role of Surgery in Portal Hypertension

Management of Severe Acute Pancreatitis

Diagnosis and Management of Choledochal Cysts

Surgery for Pancreatic Carcinoma: State of the Art

Management of Post-Cholecystectomy Benign Bile Duct Strictures: Review

Management of Pancreaticoduodenal Injuries

Update Chirurgie